Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: Evaluation by self-measurement of blood pressure at home

Tomohiro Hanazawa, Taku Obara, Kei Ogasawara, Takahiro Shinki, Sakiko Katada, Ryusuke Inoue, Hirohito Metoki, Kei Asayama, Masahiro Kikuya, Takayoshi Ohkubo, Nariyasu Mano, Yutaka Imai

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Low-dose (25 mg) or very low-dose (12.5 mg) spironolactone were added among 86 uncontrolled hypertensive patients who were undergoing monotherapy with calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin AT1-receptor blockers (ARBs). Morning home systolic/diastolic blood pressure (BP) reduction was similar among the CCB (n = 30, -8.2/-2.6 mmHg), ACEI (n = 22, -13.0/-4.7 mmHg), and ARB (n = 34, -11.5/-5.1 mmHg) groups. An increase in serum potassium correlated positively with the decline in morning systolic BP. Even very low-dose (12.5 mg) spironolactone is clinically effective, although serum potassium should be carefully monitored.

Original languageEnglish
Pages (from-to)427-436
Number of pages10
JournalClinical and Experimental Hypertension
Volume33
Issue number7
DOIs
Publication statusPublished - 2011 Nov

Keywords

  • Anti-hypertensive drugs
  • Combination therapy
  • Home blood pressure
  • Hypertension
  • Spironolactone

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology

Fingerprint Dive into the research topics of 'Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: Evaluation by self-measurement of blood pressure at home'. Together they form a unique fingerprint.

Cite this